Étiquette : LSD

Psychedelics as Medicines for Substance Abuse Rehabilitation : Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca Michael Winkelman, 2014

Psychedelics as Medicines for Substance Abuse Rehabilitation : Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca Michael Winkelman Current Drug Abuse Reviews, 2014, 7, 101-116   Abstract : Substances known as psychedelics, hallucinogens and entheogens have been employed in ethnomedical traditions for thousands of years, but after promising uses in the 1950’s and 1960’s they were largely prohibited in medical treatment and human research starting in the 1970’s as part of the fallout from the war on drugs. Nonetheless, there are a number of studies which suggest that these substances have potential applications in the treatment of addictions. While these substances are generally classified as [...]

Lire la suite

Heaven and Hell Revisited, Peter Webster, 1996

Heaven and Hell Revisited Peter Webster Composed in 1996 for The Psychedelic Library   How is it possible for two persons of such obvious intellectual talent as William Braden and Aldous Huxley to have such radically different experiences as a result of ingestion of a similar quantity of mescaline? Both Huxley and Braden brought to their first psychedelic experiment a wide knowledge and understanding of science, religion, mysticism, literature and fine arts, yet Huxley’s initial psychedelic experience was a revelation, and led to the writing of The Doors of Perception, a book which launched a movement, if not a revolution. William Braden’s experiment, recounted [...]

Lire la suite

Psychedelic drugs in the treatment of anxiety, depression and addiction, Tor-Morten  KVAM et al., 2018

Psychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten  KVAM, Lowan H. STEWART, Ole A. ANDREASSEN  Tidsskrift for Den norske legeforening, 2018. Doi : 10.4045/tidsskr.17.1110   B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is [...]

Lire la suite

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens, Adam L. Halberstadt & Mark A. Geyer, 2011

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens Adam L. Halberstadt & Mark A. Geyer Neuropharmacology, 2011, 61, (3), 364–381. doi:10.1016/j.neuropharm.2011.01.017.   Abstract Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT2 receptor agonists, whereas the indoleamines are relatively nonselective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the [...]

Lire la suite

Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia, Berit Brogaard & Dimitria Electra Gatz, 2016

Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia Berit Brogaard, Dimitria Electra Gatzia Neuropathology of Drug Addictions and Substance Misuse, 2016, Volume 2, chapter 83, 890-905. http://dx.doi.org/10.1016/B978-0-12-800212-4.00083-2 Copyright © 2016 Elsevier Inc. All rights reserved   INTRODUCTION Synesthesia typically involves either the stimulation of one sensory modality giving rise to an experience in a different sensory modality (such as when a smell or taste gives rise to a color experience) or the stimulation of a single sensory modality giving rise to an unusual qualitative experience (such as when an achromatic grapheme appears colored) (Baron-Cohen, Wyke, & Binnie, 1987; Brogaard, 2012; Cytowic, 1989; Day, 2005; Rich & Mattingley, [...]

Lire la suite

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy, James W.B. Elsey, 2017

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, Vol 3, 1-11 DOI: 10.1177/2050324517723232   Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings [...]

Lire la suite

Lysergic Acid Diethylamide and Psilocybin Revisited, Mark A. Geyer, 2015

Lysergic Acid Diethylamide and Psilocybin Revisited Mark A. Geyer Biological Psychiatry, 2015, Volume 78, Issue 8, 544-553 https://doi.org/10.1016/j.biopsych.2015.08.003   The past decade brought the beginnings of a renaissance in research on psychedelic drugs. Two articles in this issue of Biological Psychiatry signify that the resurrection of this long ignored topic has begun to mature and bear at least the promise of fruit. In the early 1970s, the onset of the “War on Drugs” brought with it a near-total hiatus in serious research on psychedelic drugs, especially in the United States. The resumption of credible work in this area has come from Switzerland, where many of [...]

Lire la suite

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects, Yasmin Schmid et al., 2014,

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H. Preller, Franz X. Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, and Matthias E. Liechti Biological Psychiatry, 2014, Vol. 78, 8, 544-553 http://dx.doi.org/10.1016/j.biopsych.2014.11.015   ABSTRACT BACKGROUND : After no research in humans for .40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with schizophrenia exhibit similar [...]

Lire la suite

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction, Nicolas A. Bercelet al., 1956

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction Nicolas A. Bercel, Lee E. Travis, Leonard B. Olinger & E. Dreikurs AMA Archives of Neurology and Psychiatry, 1956, 588-611 republishing :Psychopathology: A Source Book (pp. 605–639). DOI: https://doi.org/10.4159/harvard.9780674367012 Keywords : Cardiovascular Agents, Ergot Alkaloids, adverse effects, Lysergic Acid Diethylamide, Mental Disorders, Oxytocics, Paranoid Disorders, Psychotic Disorders INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. [...]

Lire la suite

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum, Theodore GREINER et al., 1958

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert  EDELBERG AMA, Archives of  Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]

Lire la suite